ClinicalTrials.gg
CompletedNCT03332121Updated Nov 15, 2021

B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma

A Phase 1 interventional study of B001 in CD20 Positive B Cell Non-Hodgkin's Lymphoma, sponsored by Shanghai Pharmaceuticals Holding Co., Ltd. Completed at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-11-15.

Sponsored by Shanghai Pharmaceuticals Holding Co., Ltd · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

It's the first-in-human study of Recombinant Humanized Anti-CD20 Monoclonal Antibody for Injection (B001). The main purpose of this study is to explore the safety and tolerance of B001 for patients with CD20 positive B-cell non Hodgkin's lymphoma. It will also explore the PK/PD manner and ORR in this study.

Read the detailed description

Phase I dose escalation study

02

Conditions studied

  • CD20 Positive B Cell Non-Hodgkin's Lymphoma
03

In context

Lead sponsor

Shanghai Pharmaceuticals Holding Co., Ltd is the lead sponsor of 35 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age of 18-75, male or female.
  2. Patients with the following -documented hematologic : CD20 positive B-cell non Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to 2016 WHO Classification of Lymphoma.
  3. Patients with CD20 positive B cell NHL (including CLL/SLL )
  4. of at least 6 months.
  5. -PS score of 0-1.
  6. For patients of , pregnancy test should be negative 7 days before treatment , and use of a reliable means of during the study and 12months after discontinuing treatment. Males should be willing to use barrier contraception during the study and 12months after discontinuing treatment.
  7. Provision of signed and dated ,written prior to any study specific procedures, sampling and analyses.

Exclusion criteria

Exclusion Criteria:

  1. Serious blood, renal or hepatic function impairment:

    • (ANC)\<1.0*10\^9/L(Except for those with bone marrow invasion)
    • Lymphocyte Count(LYM)>50*10\^9/L
    • (Hb)\<70g/L(Except for those with bone marrow invasion)
    • count(PLT)\<50*10\^9/L(Except for those with bone marrow invasion)
    • Creatinine (Cr)>1.5xULN
    • (ALT)or Aspartate aminotransferase(AST)>2.5xULN
    • Total (TBIL)>2xULN
  2. Patients with any anti-tumor treatment (including treatment) within 4 weeks or with any chronic unresolved toxicities from prior therapy greater than Grade 2 according to 4.03.
  3. Rituximab or any other anti-CD20 monoclonal antibody treatment within 3 weeks.
  4. received blood transfusion and hemopoietic stimulating factor,eg. colony-stimulating factor (CSF)、Erythropoietin(EPO) within 2 weeks.
  5. Radiotherapy within 3 months.
  6. Major surgery within 28 days
  7. History of tumor vaccine treatment.
  8. Live-virus (live attenuated) vaccine treatment within 28 days
  9. High dose of steroid treatment (hydroprednisone >10mg/day or relevant dose of other drugs)
  10. Patients with history of hematopoietic stem cell transplantation or planning to receive hematopoietic stem cell transplantation within 3 months.
  11. Patients with history of Gastrointestinal perforation and/or fistula within 6 months.
  12. Lymphoma in CNS, ADIS related lymphoma
  13. Active infection by bacteria,virus,fungus which required hospitalization or severe infection required intravenous administration of antibiotics
  14. Concomitant severe disease including but not limited to:

    • Known or ADIS related disease
    • Asthma or interstitial lung disease or severe
    • Myocardial infarction, unstable angina, Cardiovascular interventional surgery, Congestive heart failure(CHF; Grade II-IV), symptomatic or poorly controlled arrhythmia within 6 months before enrolling
    • The systolic pressure ≥140mmHg,or diastolic pressure≥90mmHg post treatment.
    • Acute or chronic hypotension(\<90/60mmHg)
    • History of toxic epidermal necrolysis or Stevens-Johnson syndrome
    • Rheumatoid arthritis Granulomatous angiitis or microscopic polyangiitis
    • Ileus or history of following disease: inflammatory bowel disease or extensive intestinal resection(extensive bowel resection or hemicolectomy, combining chronic diarrhea), Crohn's disease, ulcerative colitis or chronic diarrhea.
    • Previous or concomitant malignant, except basal-cell carcinoma or squamous cell carcinoma and/or cervical carcinoma in situ or effectively treated hematological and solid tumor that has been remission for more than 3 years and is considered to be cured.
    • Any history may affect the study result: increasing dosing risk or affect lab values and Judgment by the investigator that the patient should not participate in the study,
  15. positive; HBcAb positive and HBV-DNA≥upper limit of detection, positive; HIV positive
  16. Allergy to humanized antibody or human-mouse chimeric antibody.
  17. Woman who are breast feeding or pregnant
  18. Judgment by the investigator that the patient should not participate in the study
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    B001,B001 dose escalation

    5 groups with different dose: 350mg/700mg/1000mg/1500mg/2000mg

    Biological: B001

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of B001 as assessed by adverse reactions and events

    Incidence and intensity of adverse events according to NCI CTCAE 4.03 associated with increasing doses of B001

    Time frame: 42 days

Secondary outcomes

  1. Concentration-time curve of B001

    Measure the concentration of B001 in serum at different time point to get a concentration-time curve.

    Time frame: 112 days

  2. PD results of B001

    Measure the number of CD19 positive B cell in peripheral blood

    Time frame: 112 days

  3. Immunogenicity of B001

    Content analysis of anti-B001 antibody

    Time frame: 112 days

  4. ORR of B001

    Objective response rate according to Response Criteria for Lymphoma(not including PET)and CLL Response Criteria

    Time frame: 112 days

07

Study locations

2 sites
  • The second affiliated hospital of Guangzhou medical university
    Guangzhou, Guangdong, China
  • Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
    Tianjin, Tianjin 300020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Nov 2020, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2017
First posted
Nov 6, 2017
StartActual
Mar 22, 2018
Primary completionActual
Nov 30, 2020
CompletionActual
Feb 28, 2021
Last update
Nov 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03332121
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Mar 22, 2018
Primary completion
Nov 30, 2020
Completion
Feb 28, 2021
Last update
Nov 15, 2021

Study contacts

Lugui Qiu, Doctor
principal investigator · Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Junyuan Qi, Doctor
principal investigator · Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tambotatug · Anti-CD20 Monoclonal Antibody B001

Start the discussion